Production (Stage)
CureVac N.V.
CVAC
$5.57
-$0.03-0.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -99.65% | -3.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -99.65% | -3.04% | |||
| Cost of Revenue | -92.56% | -3.04% | |||
| Gross Profit | -99.99% | -3.04% | |||
| SG&A Expenses | -7.12% | -3.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 91.91% | 3.04% | |||
| Total Operating Expenses | -26.91% | -3.04% | |||
| Operating Income | -130.17% | -3.04% | |||
| Income Before Tax | -130.72% | -3.04% | |||
| Income Tax Expenses | -96.83% | -3.04% | |||
| Earnings from Continuing Operations | -133.69% | -3.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -133.69% | -3.04% | |||
| EBIT | -130.17% | -3.04% | |||
| EBITDA | -127.44% | -3.04% | |||
| EPS Basic | -133.58% | -3.04% | |||
| Normalized Basic EPS | -127.82% | -3.04% | |||
| EPS Diluted | -133.65% | -3.04% | |||
| Normalized Diluted EPS | -127.82% | -3.04% | |||
| Average Basic Shares Outstanding | 0.31% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.31% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||